Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 22, 2025Farmacia HospitalariaOpen Access

Translated article Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient

View Full Paper
Ask AI
Bookmark
Share

Authors

FOFátima Mayo OlveiraJTJosé Manuel Caro TellerMSMaría Dolores Canales Siguero

Discussion

Loading...

Member takes

Overview

Observational cohort study on ceftazidime-avibactam use during the SARS-CoV-2 pandemic, showing mortality rates in critically ill patients.

Key Points

  • Mortality rate was 41.6% overall, with no significant difference based on sars-cov-2 infection status.
  • Ceftazidime-avibactam treatment duration varied, with COVID-19 positive patients averaging 7 days and negative patients 11 days.
  • Multidrug-resistant bacteria were found in 43.8% of the patients, with klebsiella pneumoniae being the most common.
  • The pandemic did not alter the antibiotic treatment criteria for critically ill patients in the ICU.

Cite This Study

Olveira et al. (2025) studied this question.

synapsesocial.com/papers/68d43c95713b0b5dfea7ca49https://doi.org/10.1016/j.farma.2025.03.016
View Full Paper
Ask AI
Bookmark
Share